Thymuskin® has been available in Germany for many years but has more recently been introduced into the USA and many of the countries in Europe . During its development several clinical studies were published and we will now review their summaries.

In 3 clinical studies, many patients were assessed. They were suffering from Androgenetic Alopecia, Alopecia Areata and Alopecia Diffusa.

These studies clearly demonstrate that Thymuskin® can help sufferers decrease the daily loss of hair and regenerate new hair by re-growth; both in hair follicles that were in the telogen phase but also by re-activation of inactive/resting follicles. In all of these studies patients were treated with Thymuskin® Hair Treatment and Thymuskin® Shampoo.

In the tables below we can see summaries of the 3 studies and the results. In all of these studies Thymuskin® treatment was initially administered twice daily and shampoo was used daily. On the second application of treatment on each day, the hair was rinsed with water and shampoo was not applied.

In regards to alopecia diffusa this study demonstrates that there is great benefit in continuing Thymuskin usage past 6 months to the 12 months period. An increase from 73% to 87% was seen when treatment continued to 12 months.

Alopecia Totalis/Universalis is notoriously difficult to treat successfully and we feel that achieving a partial remission in 65% of patients after 9 months is excellent. Achieving complete remission (i.e. 100% success) in 40% of patients in the 9-24 month period is also excellent.

• Clinically tested in Europe for over 10 years.
• ThymuSkin strengthens the inner structure of hair.
• ThymuSkin Hair Treatment shows positive effects on hair growth in patients with all types of alopecia.
• By reactivating and rejuvenating the hair follicles ThymuSkin leads to new hair growth in men, women and children.

The following investigators were responsible for carrying out the trials on Thymuskin:

Vienna City Hospital - Austria
Dept. of Surgery
Ludwig Boltzmann Institute for Clinical Oncology
Prof. Dr. H. Denck, M.D.

Municipal Clinics of Darmstadt
University of Frankfurt
Dermatology Clinic - Director
Prof. Dr. Hagedorn, M.D.

Ruprecht - Karls University of Heidelberg
Gynecological Clinic
Prof. Dr. H.C.V Runnebaum M.D.
(Honorary)

University Clinic of Meunster
Oncology / Surgery
Dr. H. Wilke, M.D.

Medical Clinic of the University of Munich
Dept of Hematology/Oncology
Prof. Dr. Claus O. Kohler

Medical University of Hannover
Dept. of Hematology/Oncology
Dr. H. Wilke, M.D.

University of Osnabrueck, Germany
Chairman of the Division of Pharmacology and Toxicology
Prof. Dr. med. Niels Peter Lüpke M.D.

Hospital of Darmstadt, Germany
Dermatology Clinic
Prof. Dr. Claus O. Köhler M.D.